argenx SE: argenx Announces Positive Topline Phase 3 Data Fr

Study met primary endpoint, demonstrating noninferior total IgG reduction at day 29 with subcutaneously administered efgartigimod compared to intravenous (IV) administration Secondary endpoints show

Related Keywords

Japan , United States , Netherlands , United Kingdom , France , Switzerland , Belgium , America , Kelsey Kirk , Jamesf Howard Jr , Michelle Greenblatt , Beth Delgiacco , Tim Van Hauwermeiren , Instagram , Linkedin , Department Of Neurology , Twitter , Drug Administration , Exchange Commission , Immunology Innovation Program , License Application , Euronext Nasdaq , Biologics License Application , Neuromuscular Disease , Allied Health , North Carolina , Chapel Hill School , Principal Investigator , Chief Executive Officer , North America , Prescribing Information , Important Safety , Generalized Myasthenia Gravis , Looking Statements , Argenx , Nnounces , Positive , Topline , Hase , Data , Rom , Adapt , Study , Valuating , Subcutaneous , Efgartigimod , Generalized , Myasthenia , Ravis ,